The current PE ratio of CRL cannot be calculated, as the latest EPS of -$0.6 is negative. Charles River Laboratories International's last PE ratio on record was 930.8 in December 2024.
The mean historical PE ratio of Charles River Laboratories International over the last ten years is 53.32. Looking back at the last ten years, CRL's PE ratio peaked in the Dec 2024 quarter at 930.8, with a price of $186.16 and an EPS of $0.2. The Apr 2023 quarter marked the lowest point at 20.68, with a price of $201.82 and an EPS of $9.76.
Maximum annual increase: 3,550.2% in 2024
Maximum annual decrease: -52.08% in 2022
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 930.8 | 3,550.2% | $186.16 | $0.2 |
2023 | 25.5 | 11.99% | $236.4 | $9.27 |
2022 | 22.77 | -52.08% | $217.9 | $9.57 |
2021 | 47.52 | 38.74% | $369.2 | $7.77 |
2020 | 34.25 | 16.54% | $251.71 | $7.35 |
2019 | 29.39 | 24.17% | $151.93 | $5.17 |
2018 | 23.67 | -43.78% | $111.72 | $4.72 |
2017 | 42.1 | 81.78% | $109.45 | $2.6 |
2016 | 23.16 | -7.17% | $76.19 | $3.29 |
2015 | 24.95 | 5.54% | $80.08 | $3.21 |
2014 | 23.64 | -4.68% | $64.29 | $2.72 |
2013 | 24.8 | 36.49% | $53.33 | $2.15 |
2012 | 18.17 | 43.64% | $36.88 | $2.03 |
2011 | 12.65 | N/A | $27.33 | $2.16 |
2010 | N/A | N/A | $35.7 | -$5.38 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Mar 2025 | N/A | N/A | $155.55 | -$0.6 |
Dec 2024 | 930.8 | 3,679.13% | $186.16 | $0.2 |
Sep 2024 | 24.63 | 0.29% | $198.31 | $8.05 |
Jun 2024 | 24.56 | -22.5% | $206.58 | $8.41 |
Mar 2024 | 31.69 | 24.27% | $270.95 | $8.55 |
Dec 2023 | 25.5 | 21.03% | $236.4 | $9.27 |
Sep 2023 | 21.07 | -4.79% | $195.98 | $9.3 |
Jul 2023 | 22.13 | 7.01% | $210.25 | $9.5 |
Apr 2023 | 20.68 | -9.18% | $201.82 | $9.76 |
Dec 2022 | 22.77 | 4.69% | $217.9 | $9.57 |
Sep 2022 | 21.75 | -15.73% | $187.51 | $8.62 |
Jun 2022 | 25.81 | -22.52% | $226.32 | $8.77 |
Mar 2022 | 33.31 | -29.9% | $279.1 | $8.38 |
Dec 2021 | 47.52 | -17.88% | $369.2 | $7.77 |
Sep 2021 | 57.87 | 24.88% | $458.3 | $7.92 |
Stock name | PE ratio | Market cap |
---|---|---|
TMO Thermo Fisher Scientific Inc | 24.22 | $156.25B |
RGEN Repligen Corp | N/A | $7.09B |
SCYX Scynexis Inc | N/A | $32.46M |
CRL Charles River Laboratories International Inc | N/A | $6.94B |
The current price to earnings ratio of CRL cannot be determined, as its EPS of -$0.6 is negative.
As an average over the last 3 years, CRL stock has a PE ratio of 106.49.
As an average over the last 5 years, CRL stock has a PE ratio of 78.7.
Over the last ten years, the Dec 2024 quarter recorded the highest quarterly PE ratio at 930.8.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.